Cambridge, UK, 25 October 2017: SYGNIS AG today announced the launch of its Universal Lateral Flow Assay (LFA) kit, the latest addition to its expanding range of lateral flow assay products and services which are being commercialized under the Innova Biosciences brand name. The novel product provides a tool for the easy, quick development of customized sandwich lateral flow assays. This enables researchers to rapidly progress the R&D of their point-of-care (POC) diagnostic tools thereby providing physicians with faster access to POC testing for rapid early detection of disease. The company has filed a patent application to protect its newly developed product and technology.
The global market for lateral flow assays is growing at 16% per annum and projected to be worth USD 8.2 billion by 2022. This growth is driven by the rising demand for POC testing and the high prevalence of infectious diseases worldwide. The launch of the ...
